Medical Advocates
Lamivudine (Epivir)
 
Journal Citations

General Reports
Drug/Drug Interactions
 HBV Infection/Disease
 HIV Infection/Disease
 HIV/HBV Coinfection

 
 
Lamivudine Main Page Main New/Newsworthy Home Page      
Last Update:  June 29, 2008
 Documents identified with this icon are in Portable Document Format (PDF) and require the Adobe Acrobat Reader
ZDV/3TC data are indexed on the Zidovudine/Lamivudine (Combivir) Web
ABC/3TC/ZDV data are indexed on the Abacavir/Lamivudine/Zidovudine (Trizavir) Web
Perinatal Journal Data are integrated with Perinatal Conference Data in the Perinatal Data Page** Pediatric Journal Data are
integrated with Pediatric  Conference Data in the Pediatric Data Page
General Reports
 
 
Pharmacokinetics of lamivudine in subjects receiving peritoneal dialysis in end-stage renal
failure.
Asari A, Iles-Smith H, Chen YC, et al  
Br J Clin Pharmacol. 2007 Jul 27;
 Abstract
 
Dissolution test for lamivudine tablets: Optimization and statistical analysis.
Fernandes C, Junqueira RG, Campos LM, Pianetti GA.   
J Pharm Biomed Anal. 2006 Jun 21;
Abstract

Determination of lamivudine in human plasma by HPLC and its use in
bioequivalence studies.
Kano EK, dos Reis Serra CH, Koono EE, et al  
Int J Pharm. 2005 Jun 13;297(1-2):73-9.
 Abstract
Drug/Drug Interactions
 
  Antiviral and Cellular Metabolism Interactions between Dexelvucitabine and
Lamivudine.
Hernandez-Santiago BI, Mathew JS, et al
Antimicrob Agents Chemother. 2007 Apr 2;
 Abstract
HIV Infection/Disease
 

Pharmacokinetics

 
Pharmacokinetics of Lamivudine, Zidovudine, and Nevirapine Administered as a
Fixed-Dose Combination Formulation Versus Coadministration of the Individual Products.
 Marier JF, Dimarco M, Guilbaud R, et al 
J Clin Pharmacol. 2007 Nov;47(11):1381-1389.
 Abstract
 
Inhibition of HIV-1 replication in macrophages by a heterodinucleotide of lamivudine and
tenofovir.
 Rossi L, Franchetti P, Pierige F, et al 
J Antimicrob Chemother. 2007 Feb 27;
Abstract
 
Equivalent Steady-State Pharmacokinetics of Lamivudine in Plasma and Lamivudine
Triphosphate within Cells following Administration of Lamivudine at 300 Milligrams
Once Daily and 150 Milligrams Twice Daily.
Yuen GJ, Lou Y, Bumgarner NF et al.
Antimicrob Agents Chemother. 2004 Jan;48(1):176-82.
 Abstract

FULL-TEXT ARTICLE
 Population Pharmacokinetics of Lamivudine in Adult Human Immunodeficiency Virus-
Infected Patients Enrolled in Two Phase III Clinical Trials
Moore KH, Yuen GJ, Hussey EK, et al.  
Antimicrob. Agents Chemother. 1999 43: 3025-3029.  
Paper

Resistance

 
A comparison of the phenotypic susceptibility profiles of emtricitabine and lamivudine.
Borroto-Esoda K, Parkin N, Miller MD.
Antivir Chem Chemother. 2007;18(5):297-300.
 Abstract
 
A WEEK-IN-REVIEW FEATURED REPORT
Differential Impact of Thymidine Analogue Mutations on Emtricitabine and Lamivudine
Susceptibility.
Ross LL, Parkin N, Gerondelis P, et al
J Acquir Immune Defic Syndr. 2006 Oct 30;
Abstract

Limited development and progression of resistance of HIV-1 to the nucleoside analogue reverse
transcriptase inhibitor lamivudine in human primary macrophages.
Aquaro S, Svicher V, Ceccherini-Silberstein F, et al|
J Antimicrob Chemother. 2005 Apr 21;
 Abstract
 
Adverse Events
 
  Lamivudine-associated macrocytosis in HIV-infected patients.
Khawcharoenporn T, Shikuma CM, Williams AE, Chow DC.
Int J STD AIDS. 2007 Jan;18(1):39-40.
 Abstract
 
Fanconi syndrome and lactic acidosis associated with stavudine and lamivudine therapy.
Nelson M, Azwa A, Sokwala A, et al
AIDS. 2008 Jul 11;22(11):1374-6.
 Abstract

Efficacy

 
Once-Daily versus Twice-Daily Lamivudine, in Combination with Zidovudine and Efavirenz,
for the Treatment of Antiretroviral-Naive Adults with HIV Infection: A Randomized
Equivalence Trial.
DeJesus E, McCarty D, Farthing CF    
Clin Infect Dis. 2004 Aug 1;39(3):411-8.
 Abstract
 

Relative Anti-HIV-1 Efficacy of Lamivudine and Emtricitabine In Vitro Is Dependent on
Cell Type.  
Hazen R, Lanier ER.
J Acquir Immune Defic Syndr 2003 Mar 1;32(3):255-
 Abstract

Lamivudine Can Exert a Modest Antiviral Effect against Human Immunodeficiency Virus
Type 1 Containing theM184V Mutation.
Quan Y, Brenner BG, Oliveira M, Wainberg MA
 Antimicrob Agents Chemother 2003 Feb;47(2):747-54
 Abstract

Lamivudine 300 mg QD versus continued lamivudine 150 mg BID with stavudine and a
protease inhibitor in suppressed patients.
Sension MG, Bellos NC, Johnson J, et al.
HIV Clin Trials 2002 Sep-Oct;3(5):361-70
 Abstract

Nevirapine or Lamivudine plus Stavudine and Indinavir: Examples of 2-Class versus
3-Class Regimens for the Treatment of Human Immunodeficiency Virus Type 1.
 Launay O, Gerard L, Morand-Joubert L
Clin Infect Dis 2002 Nov 1;35(9):1096-105
 Abstract
 
FULL-TEXT ARTICLE
 Pharmacological Basis for Concentration-Controlled Therapy with Zidovudine, Lamivudine,
and Indinavir
Kakuda TN, Page LM, Anderson PL, et al.
Antimicrob Agents Chemother 2001 Jan;45(1):236-242
Paper

 Adolescent/Adult Treatment Indications     

FULL-TEXT ARTICLE
The Triple Combination Indinavir-Zidovudine-Lamivudine Is Highly Synergistic
Snyder S, D'Argenio DZ, Weislow O, et al.
Antimicrob Agents Chemother 2000 Apr;44(4):1051-1058
Paper
Treatment Strategies
 
     Salvage Therapy
 
  Antiviral activity of lamivudine in salvage therapy for multidrug-resistant HIV-1 infection.
Campbell TB, Shulman NS, Johnson SC  
Clin Infect Dis. 2005 Jul 15;41(2):236-42.
 Abstract
HIV/HBV Coinfection
 
 
Hepatitis B virus genotype distribution and its lamivudine-resistant mutants in HIV-coinfected
patients with chronic and occult hepatitis B.
Quarleri J, Moretti F, Bouzas MB, et al
AIDS Res Hum Retroviruses. 2007 Apr;23(4):525-31.
Abstract

Treatment of hepatitis B with lamivudine and tenofovir in HIV/HBV-coinfected patients:
factors associated with response.
Jain MK, Comanor L, White C, et al
J Viral Hepat. 2007 Mar;14(3):176-82.
 Abstract

Lamivudine Main Page Main New/Newsworthy Home Page      

Lamivudine HIV Data
Journal Papers, Abstracts, and Commentaries